Jerzy Wilczewski, a 10% Holder, acquired 3,850,000 Common Shares on a direct ownership basis at a price of $0.260 through a prospectus or prospectus exempt offering on March 11th, 2022. This represents a $1,001,000 investment into the company's shares and an account share holdings change of 19.6%.
Helix BioPharma is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.
No Comments